©2024 Stanford Medicine
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Not Recruiting
Trial ID: NCT01926990
Purpose
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response
to treatment in patients with advanced kidney cancer. Comparing results of diagnostic
procedures done before, during, and after targeted therapy may help doctors predict a
patient's response to treatment and help plan the best treatment.
Official Title
Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Stanford Investigator(s)
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Alice C. Fan
Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology
Benjamin I. Chung
Associate Professor of Urology
James D. Brooks
Keith and Jan Hurlbut Professor
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Dominik Fleischmann
Professor of Radiology (Cardiovascular Imaging)
Eligibility
Inclusion Criteria:
- Suspected or biopsy-proven renal cell carcinoma
- Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib,
nivolumab alone or in combination with an investigational agent
- Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Serum creatinine greater than or equal to 1.7 mg/dL
- Severe allergy to contrast agent
- Any contraindication for undergoing a CT scan
- Pregnancy or unwillingness to use preventative measures if a woman of child-bearing
potential
Intervention(s):
device: perfusion computed tomography
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Yoriko Imae
650-498-5186